Search alternatives:
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
481
-
482
-
483
-
484
Comparison of adhesiveness ranges for different food categories under IDDSI levels.
Published 2025Subjects: -
485
-
486
-
487
-
488
Statistical analysis of adhesiveness, hardness, and cohesiveness across IDDSI levels.
Published 2025Subjects: -
489
Comparison of hardness ranges for different food categories under IDDSI levels.
Published 2025Subjects: -
490
-
491
-
492
-
493
-
494
-
495
-
496
Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b>
Published 2025“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
-
497
-
498
-
499
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
500
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”